RT Journal Article
SR Electronic
T1 Analysis of the Second COVID-19 Wave in India Using a Birth-Death Model
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.19.21257447
DO 10.1101/2021.05.19.21257447
A1 Viswanath, Narayanan C.
YR 2021
UL http://medrxiv.org/content/early/2021/05/19/2021.05.19.21257447.abstract
AB India is witnessing the second wave of the COVID-19 disease from the first half of February 2021. The method in [5] is applied here to analyze the second wave in India. We start with fitting a birth-death model to the active and total cases data for the period from 13th to 28th February 2021. This initial dataset is expanded step by step by adding the two future week’s data to it until 14th May 2021. This resulted in six models in total. The efficacy of each model is tested in terms of predictions made for the next two weeks. The infectivity rates are found to be ever-increasing in the case of the five initial models. The infectivity rate for the sixth model, which is based on the data from 13th February to 14th May 2021, shows a decreasing nature with an increase in time. This indicates a decline in the second wave, which may start from 4th June 2021 according to the fitted parameters.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding is received for the present studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Government Engineering College, Thrissur, Kerala, IndiaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data used in the study is available at https://www.worldometers.info/coronavirus/country/india. (May 15, 2021) https://www.worldometers.info